We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eton Pharmaceuticals Inc | NASDAQ:ETON | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.78 | 12.50 | 17.00 | 7 | 09:56:48 |
From Mar 2022 to Mar 2025
By Chris Wack
Eton Pharmaceuticals Inc. said Wednesday that the U.S. Food and Drug Administration has accepted for review the company's New Drug Application response for dehydrated alcohol injection for the proposed indication of treating methanol poisoning.
The FDA has assigned a Prescription Drug User Fee Act target action date of June 27, 2023.
Eton's application has previously been granted orphan drug designation for the indication of methanol poisoning and if approved, the company expects the FDA to grant the application seven years of orphan drug exclusivity.
Eton shares were up 19% at $3.88 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 11, 2023 07:14 ET (12:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Eton Pharmaceuticals Chart |
1 Month Eton Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
